CLRB Home Investment Highlights Valuation & Metrics Price Chart Why The Stock Moved Return vs. Risk About CLRB Interactive Breakdown Better Bets vs. CLRB Peer Outperformance Latest Trefis Analyses Trade Ideas More From Trefis Peer Comparisons FDIC Bank Data FDA Approved Drugs Data Clinical Pipeline Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Forward Guidance Insider Activity Investor Activity (13F) Trade Sentinel Investor Videos Industry Resource Links External Quote Links

    Cellectar Biosciences (CLRB)

    Market Price (9/23/2026): $2.29 | Market Cap: $28.0 MilSector: Health Care | Industry: Biotechnology

    Cellectar Biosciences (CLRB)

    Market Price (9/23/2026): $2.29
    Market Cap: $28.0 Mil
    Sector: Health Care
    Industry: Biotechnology

    Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

    0

    Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -119%

    Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.

    Weak multi-year price returns
    2Y Excs Rtn is -134%, 3Y Excs Rtn is -171%

    Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0

    Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -24 Mil

    Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -86%

    Key risks
    CLRB key risks include [1] a significant funding shortfall and "going concern" warning, Show more.

    0 Cash is significant % of market cap
    Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -119%
    1 Megatrend and thematic drivers
    Megatrends include Precision Medicine, and Aging Population & Chronic Disease. Themes include Targeted Therapies, Biopharmaceutical R&D, Show more.
    2 Weak multi-year price returns
    2Y Excs Rtn is -134%, 3Y Excs Rtn is -171%
    3 Very low revenue
    Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
    4 Not profitable at operating income level
    Op Inc LTMOperating Income, Last Twelve Months is -24 Mil
    5 Yield minus risk free rate is negative
    ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -86%
    6 Key risks
    CLRB key risks include [1] a significant funding shortfall and "going concern" warning, Show more.

    CLRB in ETFs

    Weight = CLRB's share of each fund

    VTI0.00%

    Valuation & Metrics

    FYE: 12/31CLRB [1]S&P 500 [2]
    REVENUE GROWTH
    LTM Revenue [3]$0.0 Mil—
    FY 2026 Sales$3.8 Mil—
    FY 2027 Sales$7.6 Mil—
    FY 2026 Sales Growth——
    FY 2027 Sales Growth101.3%12.8%
    EARNINGS
    LTM Net Income (GAAP) [3]$-22.3 Mil—
    FY 2026 Net Income (Non-GAAP)$-6.3 Mil—
    FY 2027 Net Income (Non-GAAP)$-4.7 Mil—
    FY 2027 Net Income Growth—18.0%
    FY 2026 EPS (Non-GAAP)$-2.43—
    FY 2027 EPS (Non-GAAP)$-1.92—
    FY 2027 EPS Growth——
    VALUATION
    FY 2026 P/S7.41.6
    FY 2027 P/S3.7—
    FY 2026 P/E—7.5
    FY 2027 P/E——

    [1] CLRB forward figures are analyst consensus for the next two fiscal years (fiscal year end 12/31). Net Income and EPS are non-GAAP (adjusted) consensus. P/S and P/E divide the current market cap by the consensus figure.
    [2] S&P 500 figures are the SPY ETF's holdings-weighted forward aggregate. P/S and P/E reflect FY1/FY2 consensus blended to the 12-month window ending 9/30/27 (~one year forward), shown when ≥90% of index weight has estimates. Growth is the aggregate next-fiscal-year vs current-fiscal-year (FY1→FY2) change. Index-level dollar Sales, Net Income and EPS are not applicable.
    [3] LTM = reported trailing-twelve-month actuals (GAAP).
    null

    AI Analysis | Feedback

    MetricValueDateSource
    Number of Employees1112312024Link
    Number of Product Candidates in Pipeline512102024Link
    Planned enrollment for Phase 1b CLR 125 trial756262025Link
    Number of Recent Patents Granted410022023Link

    Price Chart

    null
    Upcoming
    11/12/2026Earnings ReleaseRev: $17 Mil (E)
    EPS: $-0.56 (E)

    Why The Stock Moved

    Qualitative Assessment

    AI Analysis | Feedback

    Updated on 9/22/2026

    Cellectar Biosciences (CLRB) stock has lost about 30% since 5/31/2026 because of the following key factors:

    1. Significant Share Dilution Risk from May 2026 Financing.

    Cellectar Biosciences filed an S-1/A in May 2026 to register the resale of up to 51,998,413 shares of common stock by existing selling stockholders, which included shares from a May 2026 private placement and shares issuable upon exercise of various warrants. This event, occurring at the beginning of the specified period, introduced a substantial dilution overhang, as the full exercise of these warrants could increase total common shares outstanding from approximately 5.8 million to 57.8 million.

    2. Increased Net Loss and Operating Expenses in Fiscal Q2 2026.

    For the fiscal quarter ended June 30, 2026, the company reported a net loss of $6.9 million, an increase from a net loss of $5.4 million in the corresponding period of the prior year. This wider loss was partly driven by a significant increase in Research and Development (R&D) expenses, which rose to approximately $4.6 million in fiscal Q2 2026 from $2.4 million in fiscal Q2 2025, due to the progression of clinical trials for iopofosine I 131 and CLR 125. The company also missed analyst EPS estimates for the quarter.

    Show more
    Updated on 9/22/2026

    Cellectar Biosciences (CLRB) stock has lost about 30% since 5/31/2026 because of the following key factors:

    1. Significant Share Dilution Risk from May 2026 Financing.

    Cellectar Biosciences filed an S-1/A in May 2026 to register the resale of up to 51,998,413 shares of common stock by existing selling stockholders, which included shares from a May 2026 private placement and shares issuable upon exercise of various warrants. This event, occurring at the beginning of the specified period, introduced a substantial dilution overhang, as the full exercise of these warrants could increase total common shares outstanding from approximately 5.8 million to 57.8 million.

    2. Increased Net Loss and Operating Expenses in Fiscal Q2 2026.

    For the fiscal quarter ended June 30, 2026, the company reported a net loss of $6.9 million, an increase from a net loss of $5.4 million in the corresponding period of the prior year. This wider loss was partly driven by a significant increase in Research and Development (R&D) expenses, which rose to approximately $4.6 million in fiscal Q2 2026 from $2.4 million in fiscal Q2 2025, due to the progression of clinical trials for iopofosine I 131 and CLR 125. The company also missed analyst EPS estimates for the quarter.

    3. Delayed New Drug Application Submission for Lead Candidate Iopofosine I 131.

    Despite positive Phase 2b clinical data for iopofosine I 131 in Waldenström Macroglobulinemia and the initiation of a confirmatory Phase 3 study, the planned New Drug Application (NDA) submission to the FDA under the accelerated approval program was announced for mid-2027. This represents a significant delay compared to earlier expectations from January 2026, which indicated NDA preparations for U.S. accelerated approval in the second half of 2024, potentially contributing to investor uncertainty.

    Show less
    Holding a concentrated position? Know your true downside before the momentum shifts.
    Protect Your Wealth →

    Stock Movement Drivers

    Fundamental Drivers

    The -29.0% change in CLRB stock from 5/31/2026 to 9/22/2026 was primarily driven by a -65.3% change in the company's Shares Outstanding (Mil).
    (LTM values as of)53120269222026Change
    Stock Price ($)3.142.23-29.0%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)412-65.3%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    5/31/2026 to 9/22/2026
    ReturnCorrelation
    CLRB-29.0% 
    Market (SPY)2.5%33.7%
    Sector (XLV)14.2%-4.7%

    Fundamental Drivers

    The -31.3% change in CLRB stock from 2/28/2026 to 9/22/2026 was primarily driven by a -74.1% change in the company's Shares Outstanding (Mil).
    (LTM values as of)22820269222026Change
    Stock Price ($)3.252.23-31.3%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)312-74.1%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    2/28/2026 to 9/22/2026
    ReturnCorrelation
    CLRB-31.3% 
    Market (SPY)13.3%28.4%
    Sector (XLV)7.0%1.3%

    Fundamental Drivers

    The -54.2% change in CLRB stock from 8/31/2025 to 9/22/2026 was primarily driven by a -86.8% change in the company's Shares Outstanding (Mil).
    (LTM values as of)83120259222026Change
    Stock Price ($)4.872.23-54.2%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)212-86.8%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    8/31/2025 to 9/22/2026
    ReturnCorrelation
    CLRB-54.2% 
    Market (SPY)21.2%25.9%
    Sector (XLV)25.8%3.1%

    Fundamental Drivers

    The -95.8% change in CLRB stock from 8/31/2023 to 9/22/2026 was primarily driven by a -96.9% change in the company's Shares Outstanding (Mil).
    (LTM values as of)83120239222026Change
    Stock Price ($)53.102.23-95.8%
    Change Contribution By: 
    Total Revenues ($ Mil)000.0%
    P/S Multiple∞∞0.0%
    Shares Outstanding (Mil)012-96.9%
    Cumulative Contribution0.0%

    LTM = Last Twelve Months as of date shown

    Market Drivers

    8/31/2023 to 9/22/2026
    ReturnCorrelation
    CLRB-95.8% 
    Market (SPY)78.3%4.8%
    Sector (XLV)34.1%5.5%

    Return vs. Risk

    Price Returns Compared

     202120222023202420252026Total [1]
    Returns
    CLRB Return-68%-74%62%-89%-67%-20%-100%
    Peers Return-7%32%41%-1%13%13%117%
    S&P 500 Return27%-19%24%23%16%13%107%

    Monthly Win Rates [3]
    CLRB Win Rate8%17%58%33%50%44% 
    Peers Win Rate42%67%58%50%83%38% 
    S&P 500 Win Rate75%42%67%75%67%56% 

    Max Drawdowns [4]
    CLRB Max Drawdown-76%-84%-33%-94%-98%-45% 
    Peers Max Drawdown-27%-19%-12%-23%-29%-15% 
    S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 

    [1] Cumulative total returns since the beginning of 2021
    [2] Peers: VRTX, APMD, ATTO, BLSM, BRVE.
    [3] Win Rate = % of calendar months in which monthly returns were positive
    [4] Max drawdown represents maximum peak-to-trough decline within a year
    [5] 2026 data is for the year up to 9/22/2026 (YTD)

    How Low Can It Go

    EventCLRBS&P 500
    2025 US Tariff Shock
      % Loss-27.5%-18.8%
      % Gain to Breakeven37.9%23.1%
      Time to Breakeven22 days79 days
    Summer-Fall 2023 Five Percent Yield Shock
      % Loss-19.2%-9.5%
      % Gain to Breakeven23.8%10.5%
      Time to Breakeven25 days24 days
    2023 SVB Regional Banking Crisis
      % Loss-21.5%-6.7%
      % Gain to Breakeven27.4%7.1%
      Time to Breakeven61 days31 days
    2020 COVID-19 Crash
      % Loss-59.1%-33.7%
      % Gain to Breakeven144.4%50.9%
      Time to Breakeven279 days140 days
    Q4 2018 Fed Policy Error / Growth Scare
      % Loss-56.7%-19.2%
      % Gain to Breakeven131.0%23.8%
      Time to Breakeven421 days105 days
    2011 US Debt Ceiling Crisis & European Contagion
      % Loss-73.6%-17.9%
      % Gain to Breakeven278.4%21.8%
      Time to Breakeven195 days123 days

    Compare to VRTX, APMD, ATTO, BLSM, BRVE

    In The Past

    Cellectar Biosciences's stock fell -27.5% during the 2025 US Tariff Shock. Such a loss loss requires a 37.9% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    EventCLRBS&P 500
    2025 US Tariff Shock
      % Loss-27.5%-18.8%
      % Gain to Breakeven37.9%23.1%
      Time to Breakeven22 days79 days
    2023 SVB Regional Banking Crisis
      % Loss-21.5%-6.7%
      % Gain to Breakeven27.4%7.1%
      Time to Breakeven61 days31 days
    2020 COVID-19 Crash
      % Loss-59.1%-33.7%
      % Gain to Breakeven144.4%50.9%
      Time to Breakeven279 days140 days
    Q4 2018 Fed Policy Error / Growth Scare
      % Loss-56.7%-19.2%
      % Gain to Breakeven131.0%23.8%
      Time to Breakeven421 days105 days
    2011 US Debt Ceiling Crisis & European Contagion
      % Loss-73.6%-17.9%
      % Gain to Breakeven278.4%21.8%
      Time to Breakeven195 days123 days
    2008-2009 Global Financial Crisis
      % Loss-63.9%-53.4%
      % Gain to Breakeven177.3%114.4%
      Time to Breakeven169 days1085 days
    Summer 2007 Credit Crunch
      % Loss-38.3%-8.6%
      % Gain to Breakeven62.0%9.5%
      Time to Breakeven662 days47 days

    Compare to VRTX, APMD, ATTO, BLSM, BRVE

    In The Past

    Cellectar Biosciences's stock fell -27.5% during the 2025 US Tariff Shock. Such a loss loss requires a 37.9% gain to breakeven.

    Preserve Wealth

    Limiting losses and compounding gains is essential to preserving wealth.

    Asset Allocation

    Actively managed asset allocation strategies protect wealth. Learn more.

    About Cellectar Biosciences (CLRB)

    Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs to treat various cancers. The company leverages its proprietary Phospholipid Drug Conjugate (PDC) platform, which is designed to selectively deliver therapeutic agents to cancer cells, aiming for more targeted and effective treatments.

    The company's lead product candidate is CLR 131 (iopofosine I-131), which is currently undergoing multiple clinical trials for different cancer types. This includes Phase 2 studies for relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and other B-cell malignancies, as well as a Phase 2B study for r/r multiple myeloma. CLR 131 is also being evaluated in Phase 1 trials for pediatric cancers, r/r head and neck cancers, and additional r/r multiple myeloma indications. Beyond CLR 131, Cellectar is developing CLR 1900, a preclinical PDC chemotherapeutic program aimed at solid tumors. Through these programs, Cellectar Biosciences targets patients with difficult-to-treat and advanced cancers, particularly those who have relapsed or are refractory to prior therapies, and also explores applications in pediatric oncology. The company also has collaborative PDC programs with several partners to expand its pipeline.

    AI Analysis | Feedback

    1. **Seagen for Phospholipid Drug Conjugates (PDCs).** (Cellectar Biosciences is developing a unique drug delivery platform, PDCs, for cancer, much like Seagen pioneered Antibody-Drug Conjugates (ADCs) for cancer treatment.)

    2. **Moderna, but developing a unique Phospholipid Drug Conjugate (PDC) platform for cancer.** (Similar to how Moderna is known for its innovative mRNA platform, Cellectar Biosciences is built around its novel PDC platform, specifically for treating various cancers.)

    AI Analysis | Feedback

    • CLR 131 (iopofosine I-131): A lead phospholipid drug conjugate (PDC) candidate currently in various clinical trial phases for the treatment of multiple cancers, including Waldenstrom's macroglobulinemia, B-cell malignancies, multiple myeloma, pediatric cancers, and head and neck cancers.
    • CLR 1900: A PDC chemotherapeutic program that is in the preclinical development stage, aimed at treating solid tumors.
    • CLR 2000 Series: A collaborative phospholipid drug conjugate program developed in partnership with Avicenna Oncology GMBH.
    • CLR 12120 Series: A collaborative phospholipid drug conjugate program developed in partnership with Orano Med.

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    • Curium US LLC
    • JSC Isotope

    AI Analysis | Feedback

    James Caruso, President, CEO and Director

    Mr. Caruso was appointed President and Chief Executive Officer and a Director of Cellectar Biosciences in June 2015. He is a life sciences executive with 37 years of professional success across multinational and specialty pharmaceutical companies, mid-tier biotechnology, and medical device start-ups. Prior to Cellectar Biosciences, he co-founded Hip Innovation Technology (HIT), a private medical device company, where he served as Executive Vice President and Chief Operating Officer. He was also Executive Vice President and Chief Commercial Officer of Allos Therapeutics, Inc., an oncology company that was acquired by Spectrum Pharmaceuticals. Additionally, Mr. Caruso served as Senior Vice President, Sales and Marketing, at Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation. His career also includes key leadership positions at multinational pharmaceutical companies such as Novartis, BASF Pharmaceuticals-Knoll, and Bristol-Myers Squibb Company.

    Chad Kolean, Chief Financial Officer

    Mr. Kolean served as Chief Financial Officer for both Vivex Biologics, a regenerative medicine company, and Titan Spine.

    Jarrod Longcor, Chief Operating Officer

    Mr. Longcor brings over 20 years of pharmaceutical and biotech experience to Cellectar Biosciences. He previously served as Chief Business Officer for Avillion LLP, where he was responsible for executing the company's co-development partnership strategy. Before Avillion, Mr. Longcor was the Vice President of Corporate Development for Rib-X Pharmaceuticals, Inc. (now Melinta Therapeutics), where he was responsible for identifying and concluding several critical collaborations for the company, including a major discovery collaboration with Sanofi Aventis valued over $700M.

    AI Analysis | Feedback

    ```html

    The key risk to Cellectar Biosciences is the inherent uncertainty and high failure rate associated with the development and regulatory approval of its drug candidates.

    Cellectar Biosciences is a clinical biopharmaceutical company with its lead candidate, CLR 131, in Phase 2 and Phase 2B clinical studies, and other programs like CLR 1900 in preclinical development. The company's future success is primarily dependent on the successful completion of these and other clinical trials, demonstrating the safety and efficacy of its drug candidates, and subsequently obtaining necessary regulatory approvals from health authorities. The drug development process is lengthy, costly, and has a historically high attrition rate, posing a significant risk to the company's ability to bring its products to market and generate revenue.

    ```

    AI Analysis | Feedback

    null

    AI Analysis | Feedback

    Cellectar Biosciences (CLRB) targets several significant addressable markets for its main product candidates.

    • Waldenstrom's Macroglobulinemia: The global market for Waldenstrom's macroglobulinemia treatment was valued at approximately USD 1.2 billion. It is projected to exceed USD 1.5 billion in the future. Another estimate places the global market at approximately $800 million in 2023, expected to reach $1.3 billion by 2030.
    • B-cell Malignancies (B-cell Lymphoma): The global B-cell lymphoma market was valued at USD 5.08 billion in 2024 and is projected to reach USD 10 billion by 2034, demonstrating a Compound Annual Growth Rate (CAGR) of 7.00% from 2025 to 2034.
    • Multiple Myeloma: The global multiple myeloma therapeutics market size was estimated at USD 20.87 billion in 2023 and is projected to reach USD 30.30 billion by 2030, growing at a CAGR of 5.5% from 2024 to 2030.
    • Pediatric Cancers: null
    • Head and Neck Cancers: The global head and neck cancer market size reached a value of USD 3,252.3 million in 2023. Looking forward, the market is expected to reach USD 7,279.8 million by 2034, exhibiting a growth rate (CAGR) of 7.6% during 2024-2034.
    • Solid Tumors: The global solid tumors market size reached a value of US$ 170.3 billion in 2023. Looking forward, the market is expected to reach US$ 375.4 billion by 2034, exhibiting a growth rate (CAGR) of 7.45% during 2024-2034.

    AI Analysis | Feedback

    Cellectar Biosciences (CLRB), a clinical biopharmaceutical company focused on cancer treatments, is expected to see its future revenue growth over the next 2-3 years driven primarily by the advancement and potential commercialization of its lead drug candidates and strategic partnerships.

    Here are 3-5 expected drivers of future revenue growth:

    1. European Commercialization of Iopofosine I-131 for Waldenstrom's Macroglobulinemia (WM): Cellectar Biosciences is on track to submit a Conditional Marketing Authorization (CMA) application to the European Medicines Agency (EMA) in the third quarter of 2026 for iopofosine I-131 (CLR 131) as a treatment for WM. The company anticipates potential European market approval and subsequent commercialization as early as 2027. Analysts' forecasts align with this, projecting the start of revenue generation around 2027-2028.
    2. U.S. Accelerated Approval and Launch of Iopofosine I-131 for WM: Cellectar has achieved alignment with the U.S. Food and Drug Administration (FDA) on a regulatory pathway for potential accelerated approval of iopofosine I-131 for WM. This is supported by the drug receiving Breakthrough Therapy Designation (BTD) from the FDA, which can expedite development and review. The FDA has also recommended studying the drug in post-BTKi settings, potentially broadening its U.S. market reach. The company expects to complete patient enrollment for a confirmatory study within 24 months from March 2025, which could pave the way for accelerated approval and an earlier market entry.
    3. Strategic Partnerships and Collaborations: Cellectar Biosciences is actively evaluating strategic collaborations for the commercialization of iopofosine I-131. Given the advanced stage of CLR 131 in Europe and its pursuit of accelerated approval in the U.S., new or expanded partnerships could generate revenue through upfront payments, milestone achievements, or future royalties within the 2-3 year timeframe. The company also has collaborative phospholipid drug conjugate (PDC) programs with various partners, which could contribute to revenue through similar mechanisms.
    4. Advancement of CLR 125 for Triple-Negative Breast Cancer (TNBC): The company initiated a Phase 1b dose-finding study for CLR 125 in triple-negative breast cancer, with early data expected by mid-2026. While direct product sales from CLR 125 are unlikely within the next 2-3 years due to its early clinical stage, positive and compelling early clinical data could significantly enhance its value, potentially leading to new collaborations, licensing deals, or milestone payments that would contribute to revenue growth within the specified period.

    AI Analysis | Feedback

    Share Issuance

    • Cellectar Biosciences completed a $6.9 million underwritten offering on July 2, 2025.
    • The company generated approximately $2.5 million from warrant exercises on June 6, 2025.
    • In October 2025, warrant inducement and related new warrants generated approximately $5.8 million in gross proceeds.

    Inbound Investments

    • Cellectar Biosciences has secured funding through 12 rounds, including 8 Post IPO rounds and 3 Grant (prize money) rounds.
    • The company completed a Post IPO funding round on September 5, 2023.
    • A Grant (prize money) funding round occurred on September 16, 2022.

    Capital Expenditures

    • Cellectar Biosciences invested $61K in capital expenditures in Q4 2024.
    • Capital expenditures were approximately $5,880 for the last 12 months and -$5,880 in 2025.
    • The average capital expenditure over the past 5 years has been $285.71K.

    Peer Outperformance in Biotechnology

    CLRB has trailed 87% of its 377 Biotechnology peers over 5Y. Biotechnology ranks 9th of 10 industries in Health Care by median 5Y return. The sector’s gains have largely come from elsewhere.
    Share of Biotechnology constituents that CLRB has outperformed, by holding period. Peers without a full price history over a given window are excluded from that window.
    1Y
    19%
    of 468 industry peers · -59.5% return
    3Y
    10%
    of 417 industry peers · -97.0% return
    5Y
    13%
    of 377 industry peers · -99.2% return
    null
    Median price return by industry across the Health Care sector, ranked by 5Y. Biotechnology is CLRB's own industry. Use this to see which corners of the sector have carried the returns.
    Industry Names 1Y med3Y med5Y med Top 3 by 5Y
    Health Care Distributors 6 19.0%46.5%91.6% CAH 382% · MCK 351% · COR 171%
    Managed Health Care 8 37.7%-6.6%0.6% OSCR 79% · HQY 41% · ELV 14%
    Health Care Services 20 19.1%35.3%-0.5% HIMS 269% · RDNT 159% · DGX 69%
    Health Care Facilities 24 5.9%13.0%-4.0% NHC 269% · THC 261% · ENSG 135%
    Health Care Equipment 50 -2.1%-0.4%-21.5% POCI 11363% · UFPT 354% · GKOS 204%
    Health Care Supplies 12 19.5%-6.4%-38.8% LNTH 270% · HAE 56% · MMSI 19%
    Pharmaceuticals 63 -6.9%13.1%-42.8% LQDA 2369% · INDV 1106% · ETON 1024%
    Life Sciences Tools & Services 113 2.5%-8.4%-67.1% SNWV 1794% · MEDP 223% · NTRA 216%
    Biotechnology ← 378 0.3%-19.9%-78.2% CELZ 1243% · DNTH 1189% · TRVI 1055%
    Health Care Technology 21 -24.3%-49.3%-78.8% SPOK 71% · HSTM 2% · VEEV -13%
    Median of constituents with a full price history over each window. Top names are unfiltered by size in this render.

    Latest Trefis Analyses

    TitleDate
    0DASHBOARDS 
    1Cellectar Biosciences Earnings Notes12/16/2025
    Title
    0ARTICLES

    Recent Active Movers

    Top Gainers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    SECZSecuritize1.963.1%5.7%
    VICRVicor12.345.9%144.8%
    ALABAstera Labs62.743.9%118.5%
    GRALGRAIL4.743.0%26.8%
    FWDIForward Industries0.741.4%30.1%
    GEMIGemini Space Station0.736.6%-40.0%
    VKTXViking Therapeutics4.736.4%16.1%
    ABSIAbsci1.734.9%206.9%
    AXTIAXT4.834.8%375.8%
    SDGRSchrodinger2.332.0%71.7%

    Top Losers

    TickerCompanyMkt Cap (B)1W RtnYTD Rtn
    XENEXenon Pharmaceuticals3.9-30.5%-12.8%
    XNDUXanadu Quantum Technologies1.7-25.9%-49.7%
    ALHCAlignment Healthcare1.7-23.0%-59.5%
    GSHDGoosehead Insurance1.1-22.9%-37.9%
    FLNCFluence Energy1.0-21.8%-63.2%
    EVEREverQuote0.7-20.1%-27.6%
    RSIRush Street Interactive2.4-18.6%9.2%
    MTDRMatador Resources6.4-17.9%24.9%
    SMSM Energy8.1-17.8%85.3%
    CTEVClaritev0.5-17.1%-31.1%

    Top Gainers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    SECZSecuritize1.9112.1%5.7%
    FWDIForward Industries0.767.3%30.1%
    SDGRSchrodinger2.355.8%71.7%
    CAPRCapricor Therapeutics0.548.5%-67.6%
    OKTAOkta34.645.5%127.4%
    ACVAACV Auctions1.840.6%30.3%
    SMTCSemtech16.240.5%136.6%
    MSTRStrategy59.040.3%10.1%
    GEMIGemini Space Station0.739.0%-40.0%
    FEIMFrequency Electronics0.837.9%58.0%

    Top Losers

    TickerCompanyMkt Cap (B)1M RtnYTD Rtn
    ALMSAlumis1.0-66.4%-16.9%
    XNDUXanadu Quantum Technologies1.7-47.2%-49.7%
    SWMRSwarmer0.4-46.7%-26.9%
    RAREUltragenyx Pharmaceutical1.6-39.5%-32.1%
    ALHCAlignment Healthcare1.7-39.3%-59.5%
    KRMNKarman4.4-37.3%-54.2%
    GSHDGoosehead Insurance1.1-36.9%-37.9%
    FLNCFluence Energy1.0-35.9%-63.2%
    XENEXenon Pharmaceuticals3.9-35.7%-12.8%
    TTANServiceTitan5.8-35.1%-42.2%

    More From Trefis

    Research & Analysis

    Invest in Strategies

    Wealth Management

    Peer Comparisons

    Peers to compare with:

    Financials

    CLRBVRTXAPMDATTOBLSMBRVEMedian
    NameCellecta.Vertex P.Apnimed Attovia .BlossomH.Bravehea. 
    Mkt Price2.23514.9925.5120.8325.2523.6124.43
    Mkt Cap0.0130.7----65.3
    Rev LTM012,5871170000
    Op Inc LTM-244,77723-74-72-31-27
    FCF LTM-193,796-84-64-65-25-45
    FCF 3Y Avg-331,957----962
    CFO LTM-194,293-84-62-64-22-42
    CFO 3Y Avg-332,398----1,183

    Growth & Margins

    CLRBVRTXAPMDATTOBLSMBRVEMedian
    NameCellecta.Vertex P.Apnimed Attovia .BlossomH.Bravehea. 
    Rev Chg LTM-10.2%----10.2%
    Rev Chg 3Y Avg-9.8%----9.8%
    Rev Chg Q-12.5%----12.5%
    QoQ Delta Rev Chg LTM-3.0%----3.0%
    Op Inc Chg LTM38.9%2,497.9%----1,268.4%
    Op Inc Chg 3Y Avg3.4%792.2%----397.8%
    Op Mgn LTM-37.9%19.9%-16,551.6%--19.9%
    Op Mgn 3Y Avg-23.9%----23.9%
    QoQ Delta Op Mgn LTM--0.2%-----0.2%
    CFO/Rev LTM-34.1%-71.5%-13,695.3%---71.5%
    CFO/Rev 3Y Avg-19.6%----19.6%
    FCF/Rev LTM-30.2%-71.5%-14,194.7%---71.5%
    FCF/Rev 3Y Avg-15.7%----15.7%

    Valuation

    CLRBVRTXAPMDATTOBLSMBRVEMedian
    NameCellecta.Vertex P.Apnimed Attovia .BlossomH.Bravehea. 
    Mkt Cap0.0130.7----65.3
    P/S-10.4----10.4
    P/Op Inc-1.227.4----13.1
    P/EBIT-1.225.9----12.4
    P/E-1.229.7----14.2
    P/CFO-1.430.4----14.5
    Total Yield-81.8%3.4%-----39.2%
    Dividend Yield0.0%0.0%----0.0%
    FCF Yield 3Y Avg-627.9%1.6%-----313.1%
    D/E0.10.0----0.0
    Net D/E-1.2-0.0-----0.6

    Returns

    CLRBVRTXAPMDATTOBLSMBRVEMedian
    NameCellecta.Vertex P.Apnimed Attovia .BlossomH.Bravehea. 
    1M Rtn-13.9%-6.0%-9.0%0.1%54.2%-14.4%-7.5%
    3M Rtn-10.8%9.9%2.0%-4.9%57.8%-20.8%-1.4%
    6M Rtn-25.9%14.8%2.0%-4.9%57.8%-20.8%-1.4%
    12M Rtn-59.5%34.4%2.0%-4.9%57.8%-20.8%-1.4%
    3Y Rtn-97.0%47.3%2.0%-4.9%57.8%-20.8%-1.4%
    1M Excs Rtn-15.1%-7.2%-10.2%-1.0%53.0%-15.6%-8.7%
    3M Excs Rtn-16.2%4.5%-3.4%-10.3%52.4%-26.2%-6.8%
    6M Excs Rtn-46.5%-3.9%-15.9%-22.9%39.8%-38.8%-19.4%
    12M Excs Rtn-73.6%17.9%-14.5%-21.4%41.3%-37.3%-17.9%
    3Y Excs Rtn-171.1%-26.9%-72.4%-79.4%-16.7%-95.2%-75.9%

    Comparison Analyses

    null

    Financials

    $ Mil | FY: 12/312026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q32024Q22024Q12023Q42023Q3
    Period End6/30/20263/31/202612/31/20259/30/20256/30/20253/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/2023
    Filing Date8/13/20265/14/20263/4/202611/13/20258/14/20255/13/20253/13/202511/18/202410/29/20245/14/20243/27/202411/13/2023
    Key Financials Quarterly            
    Total Revenue000000000000
    Ebitda-7-6-6-5-6-6-13-13-14-12-12-9
    Operating Income-7-6-6-5-6-6-13-13-14-12-13-9
    Net Income-7-6-5-4-5-7-2-15-1-27-8-18
    EPS-0.57-1.33-1.25-1.41-3.39-4.30-0.17-11.18-0.77-27.30-12.30-46.50
    Key Financials TTM            
    Total Revenue TTM000000000000
    Ebitda TTM-23-22-23-30-38-46-51-51-47-42-39-34
    Operating Income TTM-24-22-23-30-39-46-52-52-48-42-39-34
    Net Income TTM-22-21-22-19-29-25-45-50-53-62-43-45
    Growth Rates Quarterly            
    Total Revenue Growth------------
    EBITDA Growth-19.7%8.7%55.5%63.8%56.1%46.7%-1.6%-41.5%-65.2%-37.5%-69.0%-20.4%
    Operating Income Growth-19.2%9.5%55.3%63.6%55.9%46.7%-1.6%-41.6%-65.2%-37.9%-69.1%-20.4%
    Net Income Growth-27.2%14.4%-124.8%69.7%-492.6%75.2%70.1%16.3%91.0%-270.5%24.3%-124.3%
    Margins Quarterly            
    EBITDA Margin------------
    Operating Income Margin------------
    Net Income Margin------------
    Cash & Debt            
    Total Cash34813131114233426401019
    Total Debt220000011111
    Net Debt / (Cash)-32-7-13-12-11-13-23-34-25-39-9-18
    Cash Flows Quarterly            
    FCF from Operations-6-5-4-4-5-9-11-9-14-13-10-8
    Cash Flows TTM            
    FCF from Operations TTM-19-19-23-30-35-44-48-46-45-39-32-30
    Returns to Shareholders Quarterly            
    Dividends000000000000
    Share Repurchases-0-0-0-0-0-0-0-0-0-0-0-0
    Return on Invested Capital (ROIC) Quarterly            
    ROIC-10.3%-8.5%-8.6%-7.5%-9.5%-10.3%-21.3%-23.5%-25.2%-21.3%-28.1%-21.1%
    Return on Invested Capital (ROIC) TTM            
    ROIC TTM-8.4%-8.2%-8.7%-11.6%-15.1%-18.6%-21.7%-22.8%-21.9%-18.7%-21.8%-19.0%

    Segment Financials

    Net Income by Segment
    $ Mil202520242023
    Utilizing its Phospholipid Drug Conjugates (PDC) platform to develop drugs for the treatment of-22-45-43
    Total-22-45-43


    Assets by Segment
    $ Mil20232022202120202019
    Utilizing its Phospholipid Drug Conjugates (PDC) platform to develop drugs for the treatment of1222375912
    Total1222375912


    Price Behavior

    Price Behavior
    Market Price$2.23 
    Market Cap ($ Bil)0.0 
    First Trading Date11/10/2005 
    Distance from 52W High-63.9% 
       50 Days200 Days
    DMA Price$2.49$2.92
    DMA Trenddowndown
    Distance from DMA-10.5%-23.6%
     3M1YR
    Volatility37.8%78.4%
    Downside Capture139.26246.20
    Upside Capture47.1297.66
    Correlation (SPY)23.4%25.5%
    CLRB Betas & Captures as of 8/31/2026

     1M2M3M6M1Y3Y
    Beta-0.310.881.571.401.675.80
    Up Beta-0.740.111.811.171.117.86
    Down Beta1.841.151.450.981.571.32
    Up Capture-41%52%94%118%146%359%
    Bmk +ve Days10213268138427
    Stock +ve Days8162551105327
    Down Capture-10%181%193%180%168%113%
    Bmk -ve Days11213259113324
    Stock -ve Days9203367134390

    [1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
    Based On 1-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with CLRB
    CLRB-57.3%78.5%-0.74-
    Sector ETF (XLV)26.0%16.1%1.241.3%
    Equity (SPY)17.6%13.0%0.9825.6%
    Gold (GLD)18.0%29.3%0.5612.8%
    Commodities (DBC)46.6%20.7%1.75-1.7%
    Real Estate (VNQ)5.2%13.6%0.123.3%
    Bitcoin (BTCUSD)-26.0%44.9%-0.5425.9%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 5-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with CLRB
    CLRB-62.9%1,416.9%0.39-
    Sector ETF (XLV)6.8%15.2%0.264.7%
    Equity (SPY)13.3%17.2%0.594.2%
    Gold (GLD)18.9%18.8%0.81-3.7%
    Commodities (DBC)10.8%19.6%0.43-5.7%
    Real Estate (VNQ)1.0%18.9%-0.051.7%
    Bitcoin (BTCUSD)12.7%52.6%0.421.0%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How
    Based On 10-Year Data
    Annualized
    Return    		Annualized
    Volatility    		Sharpe
    Ratio    		Correlation
    with CLRB
    CLRB-56.5%1,003.2%0.26-
    Sector ETF (XLV)10.8%16.7%0.523.7%
    Equity (SPY)15.4%17.9%0.733.6%
    Gold (GLD)12.2%16.4%0.61-2.7%
    Commodities (DBC)8.3%18.1%0.37-3.8%
    Real Estate (VNQ)4.7%20.7%0.191.6%
    Bitcoin (BTCUSD)64.0%66.2%1.040.8%

    Smart multi-asset allocation framework can stack odds in your favor. Learn How

    Short Interest

    Short Interest: As Of Date8312026
    Short Interest: Shares Quantity0.2 Mil
    Short Interest: % Change Since 81520263.6%
    Average Daily Volume0.0 Mil
    Days-to-Cover Short Interest6.1 days
    Basic Shares Quantity12.2 Mil
    Short % of Basic Shares1.4%

    Earnings Returns History

    Updated 9/16/2026
    Expand for More
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/13/2026-4.6%0.8%-11.2%
    5/14/20268.8%7.8%-24.1%
    3/4/20268.2%13.8%-6.7%
    11/13/2025-18.0%-18.3%-8.6%
    8/14/20250.0%-0.2%14.9%
    5/13/2025-9.1%-3.3%61.6%
    3/13/2025-5.4%21.8%-13.8%
    11/18/2024-4.8%-15.1%-85.9%
    ...
    SUMMARY STATS   
    # Positive101012
    # Negative141412
    Median Positive3.7%9.0%12.1%
    Median Negative-5.5%-8.5%-16.9%
    Max Positive15.8%23.2%74.1%
    Max Negative-18.0%-20.0%-85.9%
     Collapse to Preview
     Forward Returns
    Earnings Date1D Returns5D Returns21D Returns
    8/13/2026-4.6%0.8%-11.2%
    5/14/20268.8%7.8%-24.1%
    3/4/20268.2%13.8%-6.7%
    11/13/2025-18.0%-18.3%-8.6%
    8/14/20250.0%-0.2%14.9%
    5/13/2025-9.1%-3.3%61.6%
    3/13/2025-5.4%21.8%-13.8%
    11/18/2024-4.8%-15.1%-85.9%
    8/13/20248.6%10.2%12.4%
    5/14/20243.9%3.3%8.8%
    3/27/2024-5.6%3.4%-21.6%
    11/2/20230.8%-12.6%8.0%
    8/14/20231.9%0.6%37.5%
    5/4/2023-2.0%-7.3%11.3%
    3/9/2023-10.5%-20.0%-26.8%
    11/3/2022-6.9%-7.4%-8.3%
    8/5/20223.5%17.0%4.8%
    5/10/2022-8.1%-10.7%-0.8%
    3/21/202215.8%23.2%17.0%
    11/8/20210.7%-7.5%-25.8%
    8/9/2021-1.9%-15.8%1.0%
    5/10/2021-2.9%-5.1%11.8%
    3/2/2021-7.5%-9.5%-19.9%
    11/9/2020-3.4%-3.4%74.1%
    SUMMARY STATS   
    # Positive101012
    # Negative141412
    Median Positive3.7%9.0%12.1%
    Median Negative-5.5%-8.5%-16.9%
    Max Positive15.8%23.2%74.1%
    Max Negative-18.0%-20.0%-85.9%

    SEC Filings

    Expand for More
    Report DateFiling DateFiling
    06/30/202608/13/202610-Q
    03/31/202605/14/202610-Q
    12/31/202503/04/202610-K
    09/30/202511/13/202510-Q
    06/30/202508/14/202510-Q
    03/31/202505/13/202510-Q
    12/31/202403/13/202510-K
    09/30/202411/18/202410-Q
    06/30/202410/29/202410-Q
    03/31/202405/14/202410-Q
    12/31/202303/27/202410-K
    09/30/202311/13/202310-Q
    06/30/202308/14/202310-Q
    03/31/202305/04/202310-Q
    12/31/202203/09/202310-K
    09/30/202211/03/202210-Q
     Collapse to Preview
    Report DateFiling DateFiling
    06/30/202608/13/202610-Q
    03/31/202605/14/202610-Q
    12/31/202503/04/202610-K
    09/30/202511/13/202510-Q
    06/30/202508/14/202510-Q
    03/31/202505/13/202510-Q
    12/31/202403/13/202510-K
    09/30/202411/18/202410-Q
    06/30/202410/29/202410-Q
    03/31/202405/14/202410-Q
    12/31/202303/27/202410-K
    09/30/202311/13/202310-Q
    06/30/202308/14/202310-Q
    03/31/202305/04/202310-Q
    12/31/202203/09/202310-K
    09/30/202211/03/202210-Q
    06/30/202208/05/202210-Q
    03/31/202205/10/202210-Q
    12/31/202103/21/202210-K
    09/30/202111/08/202110-Q
    06/30/202108/09/202110-Q
    03/31/202105/10/202110-Q
    12/31/202003/02/202110-K
    09/30/202011/09/202010-Q
    06/30/202008/10/202010-Q
    03/31/202005/07/202010-Q
    12/31/201903/09/202010-K
    09/30/201911/12/201910-Q

    Recent Forward Guidance

    Updated 8/14/2026

    Latest: Q2 2026 Earnings Reported 8/13/2026

    Forward GuidanceGuidance Change
    MetricSourceLowMidHigh% Chg% DeltaChangePrior
    Q2 2027 Cash RunwayReported      


    Prior: Q1 2026 Earnings Reported 5/14/2026

    Forward GuidanceGuidance Change
    MetricSourceLowMidHigh% Chg% DeltaChangePrior
    Q2 2027 Operational RunwayReported      

    Q4 2025 Earnings Reported 3/4/2026

    Forward GuidanceGuidance Change
    MetricSourceLowMidHigh% Chg% DeltaChangePrior
    Q3 2026 Cash RunwayReported     AffirmedGuidance: 0 for Q3 2026

    Insider Activity

    Updated 7/8/2026
    Expand for More
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Longcor, JarrodChief Operating OfficerDirectBuy51120262.888,68024,99858,899Form
    2Caruso, James VChief Executive OfficerDirectBuy51120262.888,68024,99858,516Form
    3Neis, JohnSee FootnoteSell121620253.7019873237Form
    4Caruso, James VChief Executive OfficerDirectBuy70320254.9910,00049,90058,074Form
    5Longcor, JarrodChief Operating OfficerDirectBuy70320254.9910,00049,90063,712Form
     Collapse to Preview
    #OwnerTitleHoldingActionFiling DatePriceSharesTransacted
    Value    		Value of
    Held Shares    		Form
    1Longcor, JarrodChief Operating OfficerDirectBuy51120262.888,68024,99858,899Form
    2Caruso, James VChief Executive OfficerDirectBuy51120262.888,68024,99858,516Form
    3Neis, JohnSee FootnoteSell121620253.7019873237Form
    4Caruso, James VChief Executive OfficerDirectBuy70320254.9910,00049,90058,074Form
    5Longcor, JarrodChief Operating OfficerDirectBuy70320254.9910,00049,90063,712Form
    6Kolean, Chad JChief Financial OfficerDirectBuy70320254.995,00024,95032,026Form

    Industry Resources

    External Quote Links


    Prefer one of these to Trefis? Tell us why.
    Core Cache Last Updated: 9/22/2026